CSI FOCUS D-HF: Neuromodulation in the management of heart failure and its comorbidities: diabetes, sleep apnea and hypertension

Friday, 5 February 2021


Howard Levin, Coridea, New York, USA
Felix MahfoudSaarland University Hospital, Homburg, Germany

Q&A moderator:

Marat Fudim, Duke University and the Duke Clinical Research Institute, Durham, USA

Shakeel Qureshi, Evelina Children's Hospital, London, United Kingdom



Michael Böhm, Saarland University Hospital, Homburg, Germany
Marshall Heradien, Stellenbosch University, Cape Town, South Africa

William Abraham, Ohio State University, Columbus, USA

Jörn Schmitt, University of Gießen, Gießen, Germany

Horst Sievert, CardioVascular Center Frankfurt CVC, Frankfurt, Germany

Daniel Burkhoff, Cardiovascular Research Foundation, New York, USA

Joachim Ehrlich, St. Josefs-Hospital, Wiesbaden, Germany


The top heart failure target for renal denervation...

  • … should be HFpEF >> Michael Böhm
  • … should be HFrEF >> Marat Fudim
  • … should be arrhythmias >> Marshall Heradien

Phrenic nerve stimulation with the Remede system >> William Abraham

BAROSTIM to treat HFrEF – Approved therapy for an unmet need! >> Jörn Schmitt

Endovascular ablation of the right greater splanchnic nerve >> Horst Sievert

Backbeat >> Daniel Burkhoff

Cardiac contractility modulation - How it works >> Joachim Ehrlich

An endovascular approach to Baroreflex neuromodulation >> Horst Sievert

The webinar was accredited by the European Board for Accreditation in Cardiology (EBAC) with 2 CME credits.


View on-demand

This webinar was supported by: